Director, Translational Medicine, Imaging

BlueRock Therapeutics LP; Cambridge (MA); On-site; USD 203,000 - 215,000; Full time

Job summary

BlueRock Therapeutics, a Bayer-backed company, is seeking a Director of Imaging and Biomarkers, Translational Medicine, based in Cambridge, MA. You will lead translational imaging strategies, drive biomarker development, and partner with cross-functional teams to advance CNS, ophthalmic, and inflammatory programs.

The role requires a PhD/MD/PharmD or equivalent with 6+ years in translational imaging and clinical development, plus deep MRI/PET expertise and experience in imaging core labs and CRO

Qualifications

• PhD/MD/PharmD or equivalent in Neuroscience, Biomedical Imaging, Radiology or related field.
• 6+ years in translational medicine, imaging sciences or clinical development.
• Deep expertise in clinical and translational neuroimaging (MRI and PET).
• Direct experience managing imaging protocols in clinical trials.

Responsibilities

• Develop translational imaging strategies to support clinical plans and regulatory paths.
• Lead translational imaging strategies for proof-of-mechanism and patient stratification.
• Serve as neuroimaging lead on cross-functional program teams.
• Partner with Research to characterize novel imaging biomarkers in preclinical studies.
• Develop and validate imaging methods for clinical use.
• Implement biomarker strategies to drive decision-making across stages of development.
• Lead imaging governance and expert activities (MRI, PET, SPECT, HRCT).
• Oversee CROs and vendors for imaging projects in the US, Canada, and others.

Skills

Translational imaging

MRI

PET

Clinical development

Neuroimaging

Imaging core lab

CRO management

Education

PhD, MD, PharmD or equivalent

Job description

BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary CELL+GENE™ platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases. Founded in 2016, BlueRock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.

What Are We Doing? Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies. We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.

Who is BlueRock? BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique CELL+GENE™ platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases. The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel CELL+GENE™ platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

What Are We Doing? Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit. We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.

We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting‑edge cellular therapies to impact patients’ lives.

Description of Position: It continues to be an exciting time for BlueRock Therapeutics as the company advances cutting‑edge cellular therapies to positively impact patients’ lives across multiple disease areas. The Director of Imaging and Biomarkers, Translational Medicine, will be expected to take on a highly visible role with internal and external stakeholders through the management of the imaging protocols and biomarkers leveraged in BlueRock’s clinical development programs. The Director of Imaging and Biomarkers will leverage their expertise in CNS, ophthalmic and inflammation imaging to advance the company’s development pipeline by working closely with program leads and other subject matter experts. The position will be based in Cambridge, Massachusetts.

Responsibilities

• Develop translational strategies designed to support clinical development plans, the regulatory path, and product commercialization.
• Lead the development and implementation of translational imaging strategies in support of clinical proof-of-mechanism, patient stratification, dose selection.
• Serve as the neuroimaging lead on cross-functional program teams.
• Partner with Research to discover and characterize novel imaging biomarkers in preclinical studies.
• Develop imaging methods and analytically validate imaging tools for clinical use.
• Implement clinical biomarkers and ensure biomarker‑driven decision‑making across all phases of drug development.
• Lead cross‑functional imaging governance (e.g., Imaging Steering Committee) advancing the use of imaging biomarkers to enable demonstration of disease‑modifying effects.
• Deliver subject matter expertise with respect to clinically advanced techniques in MRI, PET, SPECT, HRCT and other modalities as needed.
• Oversee CRO vendor/partners ensuring that they optimally execute clinical and preclinical imaging projects in the US, Canada, and other regions of interest.
• Provide support for the Business Development organizations as needed on diligence efforts.

Minimum Requirements

• PhD, MD, PharmD, or equivalent degree in Neuroscience, Biomedical Imaging, Radiology, or related discipline.
• 6+ years of industry experience in translational medicine, imaging sciences, or clinical development.
• Deep expertise in clinical and translational neuroimaging, including MRI and PET methodologies.
• Must have direct experience managing imaging protocols in the conduct of clinical trials (endpoints, inter‑site harmonization, imaging core lab oversight, etc.).
• Specific experience with imaging endpoints for early‑stage clinical development in CNS, ophthalmic and inflammatory diseases is desired.

Equal Opportunity Workplace

At BlueRock, we welcome and support differences and diversity and we are proud to be an equal opportunity workplace. Please let us know if you require disability‑related accommodation or other grounds protected by human rights legislation during the recruitment process so that we can work with you to meet your needs. We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.

The estimated compensation range for this position is $ 203,000.00 - $ 215,100.00 per year.

BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, one for the treatment of Parkinson’s disease and one for the treatment of primary photoreceptor diseases, are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm‑shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community‑mindedness with the understanding that we are all part of something bigger than ourselves.